Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Leefdaal – page 34

1 994 clinical trials in Leefdaal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leefdaal at a glance
1 994
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 994 trials in Leefdaal

Open in trial search

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RLY-2608
  • Sponsor:Relay Therapeutics Inc.

Breast cancer+3

Recruiting

Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Endometrial cancer+3

Recruiting

Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Corcept Therapeutics Inc.

Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-45
  • Sponsor:Entrada Therapeutics Inc.

Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of clopidogrel and acetylsalicylic acid (aspirin) for prevention of cardiovascular events in patients who survived intracerebral hemorrhage stroke

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Edinburgh

Study on the Safety and Effectiveness of Emicizumab for Patients with TYPE 3 Von Willebrand Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:F. Hoffmann-La Roche AG

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Leefdaal

What the registry says about research in the country

01 Gastroenterology Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. Research examines innovative approaches to medication management, particularly for those using proton pump inhibitors long-term.

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Treatment Optimization

The study evaluates alternative therapeutic approaches including on-demand medication use and alginate-based treatments for managing common digestive symptoms.

02 Primary Care Innovation

Investigation into patient-centered approaches for managing heartburn and reflux conditions in primary care settings. The research aims to establish more effective and personalized treatment protocols.

  • Patient-Centered Care
  • Long-term Medication Management
  • Comparative Treatment Strategies

Studies focus on determining optimal approaches to reduce long-term medication dependency while maintaining effective symptom control.

03 Therapeutic Alternatives

Research exploring the effectiveness of different therapeutic strategies for managing gastrointestinal disorders. The trials compare traditional medication tapering with newer management approaches.

  • Alternative Treatment Methods
  • Medication Reduction Protocols
  • Symptom Management Strategies

These studies aim to identify more flexible and equally effective alternatives to conventional long-term medication use.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.